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Circumventing tolerance to the prion protein (PrP): vaccination
with PrP-displaying retrovirus particles induces humoral immune
responses against the native form of cellular PrP
Abstract
Passive immunization with antibodies directed against the cellular form of the prion protein (PrPC) can
protect against prion disease. However, active immunization with recombinant prion protein has so far
failed to induce antibodies directed against native PrPC expressed on the cell surface. To develop an
antiprion vaccine, a retroviral display system presenting either the full-length mouse PrP (PrP209) or the
C-terminal 111 amino acids (PrP111) fused to the transmembrane domain of the platelet-derived growth
factor receptor was established. Western blot analysis and immunogold electron microscopy of the
retroviral display particles revealed successful incorporation of the fusion proteins into the particle
membrane. Interestingly, retroviral particles displaying PrP111 (PrPD111 retroparticles) showed higher
incorporation efficiencies than those displaying PrP209. Already 7 days after intravenous injection of
PrPD111 retroparticles, PrPC-deficient mice (Prnp(o/o)) showed high immunoglobulin M (IgM) and
IgG titers specifically binding the native PrPC molecule as expressed on the surface of T cells isolated
from PrPC-overexpressing transgenic mice. More importantly, heterozygous Prnp(+/o) mice and also
wild-type mice showed PrPC-specific IgM and IgG antibodies upon vaccination with PrPD111
retroparticles, albeit at considerably lower levels. Bacterially expressed recombinant PrP, in contrast,
was unable to evoke IgG antibodies recognizing native PrPC in wild-type mice. Thus, our data show
that PrP or parts thereof can be functionally displayed on retroviral particles and that immunization with
PrP retroparticles may serve as a novel promising strategy for vaccination against transmissible
spongiform encephalitis.
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Passive immunization with antibodies directed against the cellular form of the prion protein (PrPC) can
protect against prion disease. However, active immunization with recombinant prion protein has so far failed
to induce antibodies directed against native PrPC expressed on the cell surface. To develop an antiprion vac-
cine, a retroviral display system presenting either the full-length mouse PrP (PrP209) or the C-terminal 111
amino acids (PrP111) fused to the transmembrane domain of the platelet-derived growth factor receptor was
established. Western blot analysis and immunogold electron microscopy of the retroviral display particles
revealed successful incorporation of the fusion proteins into the particle membrane. Interestingly, retroviral
particles displaying PrP111 (PrPD111 retroparticles) showed higher incorporation efficiencies than those dis-
playing PrP209. Already 7 days after intravenous injection of PrPD111 retroparticles, PrPC-deficient mice (Prnpo/o)
showed high immunoglobulin M (IgM) and IgG titers specifically binding the native PrPC molecule as ex-
pressed on the surface of T cells isolated from PrPC-overexpressing transgenic mice. More importantly, het-
erozygous Prnp/o mice and also wild-type mice showed PrPC-specific IgM and IgG antibodies upon vaccination
with PrPD111 retroparticles, albeit at considerably lower levels. Bacterially expressed recombinant PrP, in con-
trast, was unable to evoke IgG antibodies recognizing native PrPC in wild-type mice. Thus, our data show that
PrP or parts thereof can be functionally displayed on retroviral particles and that immunization with PrP retro-
particles may serve as a novel promising strategy for vaccination against transmissible spongiform encephalitis.
Prion diseases, also called transmissible spongiform enceph-
alopathies, are a group of fatal neurodegenerative conditions
that affect humans and a wide variety of animals. To date there
is no therapeutic or prophylactic approach against prion dis-
eases available. However, several recent studies with cell cul-
tures as well as with mice suggest that immunotherapeutic
strategies directed against the native cellular form of the prion
protein (PrPC) might be effective in preventing or curing prion
diseases (7, 9, 21, 25, 28, 33). Furthermore, recent studies
involving transgenic mice with a skewed anti-PrPC B-cell rep-
ertoire (6H4) suggest that in principle the immune system
does allow the development of PrPC-specific B cells, even if
endogenous PrPC is expressed (14).
However, active induction of an immune response against
native PrPC or its disease-associated conformer (PrPSc) has
proven to be rather difficult in wild-type mice; i.e., immunization
of wild-type mice with recombinant full-length PrP (PrPREC)
or peptides thereof resulted in the induction of antibodies that
bound PrPREC coated to plastic, but these antibodies failed to
recognize native PrPC as expressed on the cell surface. This phe-
nomenon was further analyzed in different transgenic mouse
lines with aberrant PrP expression. Interestingly, among the
tested mice, only those expressing PrP under control of an oli-
godendrocyte and Schwann cell-specific promoter (MBP-PrP
mice) were able to mount antibodies directed against native
PrPC (22). In a recall assay, lymph node cells from MBP-PrP
mice showed moderate proliferation, whereas lymph node cells
from all other PrP-expressing mice tested did not proliferate
(22). Since MBP-PrP mice are resistant to prion infection, the
protective capacity of actively induced native PrPC-specific an-
tibodies could not be assessed in that model. Nevertheless, the
results suggested that the difficulties in inducing native PrPC-
specific antibody responses most likely resulted from host tol-
erance to the endogenously expressed PrPC.
Thus, to overcome host tolerance to PrPC and to activate
PrP-specific B cells, we aimed at defining conditions or im-
mune regimens that resulted in anti-PrP antibody titers in
wild-type mice. Reasoning that recombinant virus-like parti-
cles (VLPs) are better B-cell immunogens than monovalent
recombinant proteins, we developed a retrovirus-based display
system for PrP.
C-type retroviruses are enveloped particles that assemble at
the plasma membrane. Particle formation is driven by the Gag
protein precursor, which is processed by the viral protease to
form the matrix protein (MA) and the capsid protein (CA).
When expressed in an appropriate eucaryotic environment, the
gag-encoded proteins self-assemble into noninfectious VLPs
which bud from the producer cell in the absence of the viral
envelope protein (26). Moreover, retroviruses can incorporate
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foreign transmembrane proteins into the envelope, as has been
shown in the case of human immunodeficiency virus (HIV)-
expressing complement regulatory proteins such as CD55 (20).
Although the molecular basis for the incorporation of foreign
surface molecules in retroviruses is not fully understood, over-
expression of surface receptors of Gag-expressing cells is usu-
ally one critical requirement.
We used the prototype of C-type retroviruses, murine leu-
kemia virus (MLV), to set up the display of PrP on retrovirus-
like particles. We show that upon overexpression of PrP, MLV-
derived VLPs that display PrPC can be generated. Moreover,
these PrP retroparticles proved to be highly immunogenic in
PrPC-deficient mice and, even more importantly, evoked native
PrPC-specific antibody responses in wild-type mice.
MATERIALS AND METHODS
Generation of PrP display constructs. For construction of pDisplay (Invitro-
gen)-based expression constructs, three different coding regions of murine PrP,
i.e., amino acids 23 to 231 (PrP209), amino acids 90 to 231 (PrP142), and amino
acids 121 to 231 (PrP111), as well as the region encoding amino acids 1 to 52 of
the human epidermal growth factor (EGF) molecule, were amplified as 665-,
465-, 376-, and 245-bp PCR fragments, respectively, by using oligonucleotides
5-GTATGGCCCAGCCGGCCAAAAAGCGGCCAAAGC-3 (forward 209),
5-GTATGGCCCAGCCGGCCCAAGGAGGGGGTAC-3 (forward 142), 5-G
ACTGGCCCAGCCGGCCGTGGGGGGCCTTGGTGGCTACATGC-3 (for-
ward 111), 5-GACTCCGCGGCCTTCCCTCGATGCTGGATCTTCTCCCGT
CG-3 (reverse PrP), 5-GCGGCCCAGCCGGCCGATTATAAGGACGACGA
TGATAAGGCTAGCGCAATAGTGACTCTGAGTGTCC-3 (forward EGF),
and 5-TCCCCGCGGTGCGGCCGCCCTTCCCTCGATAGC-3 (reverse
EGF) and the PrP-encoding plasmid phgPrP (8) or the EGF-encoding plasmid
pTC53-EGF (17) as the template. In these primer sequences, the SfiI and SacII
restriction sites are in boldface and the factor Xa cleavage sites are underlined.
Upon subcloning of PCR products and sequence verification, SfiI/SacII frag-
ments were ligated into SfiI- and SacII-digested pDisplay (Invitrogen), resulting
in the display constructs pD-PrP111, pD-PrP142, pD-PrP209 and pD-EGF.
Cells and mice. Human embryonic kidney (HEK)-293FT cells (Invitrogen,
catalog no. R700-07) and murine neuroblastoma N2A cells (ATCC CCL-131)
were cultivated in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum, benzylpenicillin (60 g/ml), and streptomycin (100 g).
PrP-deficient (Prnpo/o) mice (3) and tg33 transgenic mice overexpressing PrP
specifically on T cells (23) were bred under specific-pathogen-free conditions at
the central mouse facility of the Paul-Ehrlich-Institut. Unmutated C57BL/6 mice
(referred to as wild-type [Prnp/]) were purchased from Charles River Labo-
ratory or were bred at the Paul-Ehrlich-Institut. Heterozygous mice carrying one
Prnp knockout allele and one wild-type allele (Prnp/o) were obtained by cross-
ing Prnpo/o mice with C57BL/6 mice. The genotypes of Prnpo/o and Prnp/o mice
were verified by a combined PCR approach with primers P3 (5-ATTCGCAG
CGCATCGCCTTCTATCGCC-3), P10 (5-GTACCCATAATCAGTGGAAC
AAGCCCAGC-3), and P3NC (5-CCCTCCCCCAGCCTAGACCACGA-3),
identifying the wild-type and the targeted Prnp allele as a 500- and 300-bp PCR
products, respectively. Experimental mouse work was carried in compliance with
the regulations of the German animal protection law.
Production of PrP retroparticles. Three T175 flasks containing HEK-293FT
cells grown to subconfluency were transiently cotransfected with the MLV gag/
pol expression plasmid pHIT60 (29) and the PrP or EGF display construct,
respectively. For transfection, 45 g of each of the two plasmids were mixed with
90 l of Lipofectamine and 180 l of Plus reagent (Invitrogen). Cell culture
supernatant was harvested twice, at 48 and 72 h after transfection, and particles
were concentrated by low-speed centrifugation (3,600 rpm, 4°C, Biofuge; Hae-
reus) or by centrifugation through a sucrose cushion (35,000 rpm, 4°C, Beckman
SW41). The pelleted virus was resuspended in 1 ml of phosphate-buffered saline
(PBS) and used for electron microscopy, immunization experiments, and West-
ern blot analysis. Sucrose cushion-purified particles and particles concentrated by
low-speed centrifugation were equally immunogenic. However, low-speed cen-
trifugation was routinely used, as this resulted in higher particle numbers. For
quantification of particle numbers, reverse transcriptase (RT) activity was deter-
mined with a C-type RT activity kit (Cavidi Tech), and enzyme-linked immu-
nosorbent assay (ELISA) tests were performed (see below).
Immunofluorescence. N2a cells were transfected and 48 h later were fixed with
2% formaldehyde in PBS. Fixed cells were stained with the anti-PrP mouse
monoclonal antibody 6H4 (Prionics) or the anti-human EGF mouse monoclonal
antibody EGF-10 (Sigma). To detect the MLV CA protein in double stainings,
samples were additionally incubated with the goat anti-MLV p30 serum (Quality
Biotech). Fluorescein isothiocyanate (FITC)-conjugated anti-mouse immuno-
globulin (Ig) (Dianova) and Cy3-conjugated anti-goat Ig (Dianova) were used as
secondary antibodies.
Western blot analysis. Transfected HEK-293FT cells were harvested 48 h after
transfection and lysed in radioimmunoprecipitation assay lysis buffer (25 mM
Tris [pH 8], 137 mM NaCl, 10% glycerol, 0.1% sodium dodecyl sulfate, 0.5%
sodium deoxycholate, 1% NP-40, 2 mM EDTA). The cell culture supernatant
was filtered (Sartorius 0.45-m-pore-size filter), and particles were purified by
centrifugation through a sucrose cushion (35,000 rpm, 4°C, Beckman SW41). For
deglycosylation, 7.5 l of concentrated particles was incubated with 10 U of
peptide N-glycosidase F (PNGase F) enzyme (New England Biolabs). Buffer
conditions, incubation times, and temperatures were according to the manufac-
turer’s instructions. Samples were separated on sodium dodecyl sulfate–16%
polyacrylamide gels and then transferred to a nitrocellulose membrane (Hybond
ECL; Amersham). Protein detection was achieved with the antihemagglutinin
(anti-HA) mouse monoclonal antibody 12CA5 (Roche), the anti-PrP monoclonal
antibody 6H4 (Prionics), or goat anti-MLV p30 serum (Quality Biotech). As the
secondary antibody, horseradish peroxidase (HRP)-conjugated rabbit anti-goat
Ig (Dako) or goat anti-mouse Ig (Sigma) was used. Bands were visualized by
using the SuperSignalPico chemiluminescence kit (Pierce) and a LumiImager
(Roche).
Electron microscopy. For detection of PrP displayed on retrovirus particles,
ultrathin frozen sections of virus-producing cells or virions concentrated from the
cell supernatant were used. Ultrathin frozen sections were prepared as described
by Tokuyasu and Singer (32). Cells were fixed with a mixture of 2% formalde-
hyde and 0.1% glutaraldehyde for 1 h. After being washed, the fixed cells were
embedded in warm liquid agarose, which after gelling could be cut into small
blocks. These blocks were immersed overnight in 2.3 M sucrose containing 10%
polyvinylpyrrolidone, frozen in liquid nitrogen, and cut into 80- to 100-nm sec-
tions with an ultramicrotome (Ultracut E; Reichert, Vienna, Austria) with cryo-
equipment. Sections were mounted on carbon-coated Formvar grids and, after
thawing, washed with PBS. After treatment with 2% bovine serum albumin
(BSA), the grids were incubated with the 6H4 antibody at a 1:750 dilution. After
being rinsed in PBS, grids were incubated with anti-mouse IgG (1:100 dilution)
coupled to 10-nm-diameter gold particles (BioCell). Finally, to embed and stain
structures, the grids were floated, sections down, on 1.6% methylcellulose con-
taining 0.2% uranyl acetate for 5 min. Excess methylcellulose was aspirated
before the resulting thin film was air dried (10).
For immunonegative staining, 20 l of virus suspension was adsorbed to
glow-discharged carbon-coated Formvar grids for 2 min. After being rinsed in
PBS, the grids were incubated with 2% BSA for 30 min and with the 6H4 or
anti-EGF primary antibodies at a 1:750 dilution for 1 h. After being washed, grids
were incubated with a 1:100 dilution of 10-nm-diameter-gold-labeled anti-mouse
IgG (BioCell, Cardiff, United Kingdom) for 30 min. Finally, immunolabeled
viruses were negatively stained with 2% uranyl acetate or phosphotungstate for
10 s.
Electron microscopy preparations were examined in a Zeiss EM 109 or 902
electron microscope, and micrographs were taken on Kodak Estar electron
microscope film.
Immunization of mice. Prnpo/o, Prnp/o, and C57BL/6 mice, 2 to 3 months of
age, were immunized by intravenous (i.v.) injection of approximately 1011 retro-
viral particles displaying PrP111 (PrPD111 retroparticles) in 200 l of PBS.
Booster injections were performed 14 days after primary immunization. Blood
was taken weekly to monitor the antibody reactivity. For immunizations in the
presence of various adjuvants, PrPD111 retroparticles were emulsified in an equal
volume of cytidylguanyl oligodeoxynucleotides (CpG1668) (50 g/mouse; 1:2),
Titer Max (1:2), alum (1:2), or complete Freund’s adjuvant (CFA) and incom-
plete Freund’s adjuvant (IFA) (1:2) immediately before subcutaneous (s.c.)
administration (100-l total volume). All adjuvants were obtained from Sigma.
For boosting upon priming with PrPD111 retroparticles in CFA, IFA was used.
Analysis of PrP-specific antibodies by ELISA. Expression and purification of
recombinant mouse PrP amino acids 121 to 231 (PrPREC121-231) was performed
as described previously (15, 35). In brief, the expression plasmid pRSETa
mPrP(121–231) fused to an N-terminal histidine tag was transformed into Esch-
erichia coli BL21(DE3) (Invitrogen). Bacteria were grown to an optical density at
600 nm of 0.5 and then induced with 1 mM isopropyl--D-galactopyranoside
(IPTG) (Sigma). Cells were harvested 6 h after induction, centrifuged, and
resuspended in 6 M guanidinium hydrochloride–5 mM Tris-HCl–100 mM
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Na2PO4–10 mM reduced glutathione (pH 8.0). After sonication and centrifuga-
tion, the soluble protein fraction was added to a nickel-nitrilotriacetic acid
agarose resin (Qiagen) for purification.
The wells of 384-well ELISA plates were coated with 5 g of PrPREC121-231 per
ml in PBS and blocked with 5% BSA. Twenty-fold-prediluted sera were serially
twofold diluted (20 log2) in PBS–0.1% Tween–1% BSA and added to the ELISA
plates. After 2 h of incubation at room temperature, the plates were thoroughly
washed and 1:1,000-diluted HRP-conjugated polyclonal rabbit antibody directed
against mouse IgM, IgG, and IgA (anti-mouse IgMGA; Zymed) was added.
After 1 h of incubation at room temperature plates were washed, and for the
detection of bound HRP-coupled antibodies, substrate (0.5 mg of 2,2-azino-di-
ethylbenzothiazolinsulfonate [Roche] per ml in 0.1 M NaH2PO4 [pH 4] and 30%
H2O2) was added. The optical density was determined at a wavelength of 405 nm.
To quantify molecules displayed on retroparticles, purified PrP or EGF ret-
roparticles were prediluted 1:10 in 0.1 M NaHCO3 (pH 9.6) and then serially
threefold diluted (10 log3) and applied to 96-well ELISA plates (Nunc). Upon
blocking with 5% BSA, 6H4 or anti-p30 antibodies prediluted in PBS–0.1%
Tween–1% BSA were added and left for 2 h at room temperature. After thor-
ough washing, bound antibody was decorated with 1:1,000-diluted HRP-conju-
gated rabbit anti-mouse IgMGA antibody (Zymed).
Flow cytometric determination of PrPC-specific serum binding. For flow cy-
tometric determination of PrPC-specific serum antibody binding, heparinized
tg33 mouse blood diluted in PBS–2% fetal calf serum–0.03% NaN3–20 mM
EDTA (pH 8) was incubated for 20 min at 4°C with either sera of immunized
mice, 6H4 as a positive control, isotype controls, or normal mouse serum to-
gether with phycoerythrin-conjugated anti-CD3 (Caltag). After washing, blood
cells were incubated for 20 min at 4°C with FITC-conjugated donkey anti-mouse
IgG (Dianova) or goat anti-mouse IgM (Caltag) and then subjected to red blood
cell lysis and fixation with fluorescence-activated cell sorter (FACS) lysing solu-
tion (Becton Dickinson) according to the manufacturer’s instructions. Samples
were analyzed on a FACScan machine (Becton Dickinson) by acquiring 10,000
events in the lymphocyte gate. Data analysis was performed with the Cell Quest
software (Becton Dickinson).
RESULTS
Generation and characterization of PrP retroparticles. To
generate PrP displaying VLPs, expression constructs encoding
either the full-length PrP covering codons 23 to 231 (PrP209)
or the C-terminal fragment covering codons 90 to 231 (PrP142)
or 121 to 231 (PrP111) were generated. For this, fragments
encoding the respective PrP portions were ligated into the
pDisplay vector, encoding the murine immunoglobulin  chain
signal peptide at the N terminus and the transmembrane do-
main of the platelet-derived growth factor receptor (PDGFR)
at the C terminus (4, 6). Thus, PrP fusion proteins D-PrP111,
D-PrP142, and D-PrP209 expressed from the resulting plas-
mids contained HA and Myc tags for easy detection and a
factor Xa cleavage site for preparation of soluble PrP fusion
proteins (Fig. 1). We used this strategy initially to produce
EGF-displaying retroviral particles, which were used as nega-
tive control particles in this study (Fig. 1).
To verify proper expression of the fusion proteins, the hu-
man cell line HEK-293FT and the murine neuroblastoma cell
line N2a were transiently transfected with plasmid pD-PrP111,
pD-PrP209, or pD-EGF and analyzed by immunofluorescence
staining. Strong and specific cell surface staining was found for
the D-EGF (Fig. 2B) and the D-PrP111 (Fig. 2F) proteins,
while only weak signals were detected for the D-PrP209 pro-
tein (not shown). Thus, compared to endogenous PrP levels in
N2a cells (Fig. 2D), strong overexpression of the D-PrP111
protein was achieved (Fig. 2F). Upon coexpression of the
MLV gag and pol genes, colocalization of the MLV CA protein
with the D-PrP111 or the D-EGF molecules at the cell surface
was demonstrated (Fig. 2C and G).
To generate retroviral particles displaying the protein D-
PrP209, D-PrP142, D-PrP111, or D-EGF, HEK-293FT cells
were transfected with the different expression plasmids, pD-
PrP209, pD-PrP142, pD-PrP111, and pD-EGF, in combination
with pHIT60 (carrying the MLV gag and pol genes), respec-
tively. As no packagable nucleic acid was provided, noninfec-
tious VLPs were generated. Cell lysates and particle prepara-
tions were analyzed by Western blotting using an anti-HA
tag-specific antibody and the PrP-specific antibody 6H4. All
D-PrP variants showed the typical pattern of at least three
different variants of PrP, i.e., un-, mono-, and diglycosylated
protein, at the expected molecular weights (Fig. 3A to C). In
line with the results of the immunofluorescence analysis, stron-
ger signals were obtained for the D-PrP111 protein, while only
faint bands were detected for the D-PrP209 protein (Fig. 3A).
In the particle fraction, the D-PrP111 and D-PrP142 proteins
as well as the D-EGF protein were readily detectable, suggest-
ing that they were incorporated into retrovirus-like particles.
In fact, incorporation of the D-PrP111 protein even seemed to
exceed that of the D-EGF protein (Fig. 3B, compare lanes 1
and 2).
Moreover, the incorporated D-PrP111 and D-PrP142 pro-
teins were fully glycosylated (see PNGase F treatment in Fig.
3C, lane 3) and easily detectable by the 6H4 antibody (Fig. 3C,
lanes 2, 3, 5, and 6). In contrast, the D-PrP209 protein was
incorporated at a considerably lower level. Only when 40-fold-
higher particle numbers were used in Western blot analysis did
the D-PrP209 protein become detectable (Fig. 3B, lane 3).
FIG. 1. Schematic representation of the display expression constructs. The pDisplay expression plasmid (Invitrogen) provides the immuno-
globulin signal peptide (SP), the HA and Myc tags, and the transmembrane domain of the PDGF receptor (PDGFR-TM). In addition, a factor
Xa cleavage site was inserted N terminal to the PDGFR-TM.
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This was not due to reduced particle release in presence of the
D-PrP209 protein, as the MLV capsid protein p30 was found to
be present in similar amounts in the cell culture supernatants
of pD-PrP209/pHIT60- and pD-PrP111/pHIT60-transfected
cells (Fig. 3B). Thus, due to higher cell surface expression lev-
els and increased particle incorporation rates, the D-PrP111
protein allowed the production of particle stocks containing at
least 100-fold-larger amounts of PrP than stocks of PrPD209
retroparticles.
In addition to Western blot analysis, the particles were sub-
jected to ELISA analysis by applying log3 dilutions of concen-
trated stocks (100 RT units/ml) to ELISA plates and analyzing
anti-PrP and anti-p30 binding. While PrPD111 retroparticles
showed strong binding of the PrP-specific 6H4 antibody and of
the anti-p30 antibody, EGFD retroparticles showed no 6H4
binding but strong anti-p30 binding (Fig. 3D). Therefore,
throughout this study the ELISA was used to standardize par-
ticle preparations for immunization purposes.
To further verify the identity of PrP-displaying retropar-
ticles, transfected cells and particle preparations were sub-
jected to electron microscopic analysis using immunogold
labeling of the 6H4 antibody. Sections of HEK-293T cells
transfected with pD-PrP111/pHIT60 showed a strong and spe-
cific accumulation of gold particles along the cell membrane.
Gold particles were also found at sites of cytoplasmic extru-
sions, which in part had a virus particle-like morphology (Fig.
4a). Stocks of PrPD111 particles contained particles with a typ-
ical C-type retrovirus morphology as well as pleomorphic,
vesicle-like structures (Fig. 4b and c). Both were specifically
stained at their surrounding membranes. The controls, i.e., PrP
retroparticles treated with the gold-labeled antibody only or
EGF-displaying particles treated with both antibodies, did not
show any staining (data not shown and Fig. 4e), whereas EGFD
retroparticles showed specific surface staining with an EGF-
specific antibody (Fig. 4d).
Induction of PrP-specific antibody responses in mice. To
verify the antigenicity of the PrPD111 retroparticles, Prnpo/o
mice, which are devoid of endogenously expressed PrPC, and
Prnp/o and Prnp/ mice, which express either one or two Prnp
alleles, respectively, were immunized i.v. with approximately
1011 PrPD111 retroparticles, and serum was taken weekly. Al-
ready 7 days after immunization, Prnpo/o mice showed high
titers of PrP-specific antibodies as indicated by an ELISA de-
tecting PrP-specific IgM, IgG, and IgA (Fig. 5A). Interestingly,
despite the expression of one or two Prnp alleles, Prnp/o and
Prnp/ mice also mounted PrP-specific antibody responses,
albeit at substantially reduced levels compared to Prnpo/o mice
(Fig. 5B and C). Essentially similar response curves were found
with sera obtained 14 days after immunization (data not
shown). PrP-specific antibody responses in Prnp/ mice were
slightly lower than those in Prnp/o mice, which might be ex-
plained by a higher level of PrP-specific tolerance in Prnp/
mice than in Prnp/o mice.
Next we studied whether serum antibodies showing PrP-
specific binding in an ELISA also bind the native form of PrPC
as expressed on the cell surface. To this end, peripheral blood
was taken from tg33 mice overexpressing PrP on T lympho-
cytes (23), and CD3-positive T cells were tested for binding of
serum IgM or IgG derived from immunized mice by FACS
analysis.
Seven days after immunization of Prnpo/o mice, serum
showed PrPC-specific IgM binding that was slightly decreased
by day 14, whereas strong PrPC-specific IgG binding was de-
tected on day 7 and was further increased by day 14, even
beyond the binding strength of the positive control 6H4 (Fig.
6A and B). Reminiscent of the ELISA results described above,
7 days after immunization of Prnp/o mice, serum showed
PrPC-specific IgM binding that was slightly lower than that of
Prnpo/o mice and slightly higher than that of Prnp/ mice (Fig.
6A), whereas 14 days after immunization, PrPC-specific IgM
was not detectable in sera of either Prnp/o or Prnp/ mice
(Fig. 6B). Compared to that in sera of Prnpo/o mice, PrPC-
specific IgG binding was substantially reduced in the sera
of Prnp/o and Prnp/ mice, whereas sera of Prnp/o mice
showed slightly higher binding than those of Prnp/ mice.
Interestingly, some PrPC-specific IgG was still detectable 14
days after immunization (Fig. 6B).
To verify the specificity and reliability of the FACS method
FIG. 2. Display constructs encoding EGF and PrP fusion proteins
give rise to high surface expression on transiently transfected N2A
cells. N2A cells were transfected with plasmids pD-EGF and pHIT60
(A to D) or pD-PrP111 and pHIT60 (E to H). Cells were stained with
anti-PrP (-PrP) antibody 6H4 (D and F), with anti-EGF antibody (B),
or with anti-p30 antiserum (A and E), and bound antibody was de-
tected with FITC-conjugated anti-mouse Ig (B, F, D, and H) or Cy3-
conjugated anti-goat Ig (A and E). The merge of A and B is shown in
panel C, and that of E and F is shown in panel G.
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used for determination of PrPC reactive antibodies, a number
of control experiments were performed. First, N2A neuroblas-
toma cells and tg33-derived T cells incubated with 6H4 anti-
body or various different PrP-reactive immune sera showed
very similar stainings, indicating that the tg33-based FACS
method revealed binding of PrPC as expressed on normal cells
(data not shown). Second, a potential interindividual hetero-
geneity with respect to spontaneous PrP-specific antibody ti-
FIG. 3. The display proteins are incorporated into retroviral particles. Display and capsid proteins were detected by Western blot analysis with
16% polyacrylamide gels or by ELISA. (A) HEK-293FT cells were transfected with the pHIT60 plasmid and pD-EGF (lane 1), pD-PrP111 (lane 2),
pD-PrP209 (lane 3), or an unrelated control plasmid (lane 4). Cell extracts were analyzed with the anti-HA (HA) antibody. (B) Supernatants of
HEK-293FT cells transfected with pHIT60/pD-EGF (lane 1), pHIT60/pD-PrP111 (lane 2), or pHIT60/pD-PrP209 (lane 3) were concentrated by
low-speed centrifugation. Pellets were resuspended in PBS. Western blotting was performed with the anti-HA antibody in the upper blot and with
anti-p30 serum to detect the MLV capsid in the lower blot. Volumes loaded corresponded to the following amounts of cell culture supernatant:
0.7 ml (lane 1, upper blot), 0.35 ml (lane 2, upper blot), and 13.5 ml (lane 3, upper blot). Volumes loaded on the lower blot corresponded to 1
ml of cell culture supernatant each. (C) Supernatants of HEK-293FT cells transfected with pHIT60/pD-EGF (lane 1), pHIT60/pD-PrP111 (lanes
2, 3, and 5), pHIT60/pD-PrP209 (lane 4), or pHIT60/pD-PrP142 (lane 6) were detected with the anti-PrP antibody 6H4. For PNGase F digestion,
particles were equilibrated in denaturing buffer and incubated in the presence (lane 3) or absence (lane 2) of PNGase F. Volumes loaded on the
gels correspond to 0.7 ml (lane 1), 0.35 ml (lanes 2 and 3), 13.5 ml (lane 4), 0.8 ml (lane 5), and 1.2 ml (lane 6) of cell culture supernatants.
(D) Analysis of PrPD111 retroparticles (upper panel) and of EGFD retroparticles (lower panel) by ELISA. Concentrated stocks of both particle
types were applied to ELISA plates at the indicated dilutions. Virally expressed antigens were detected by use of the anti-PrP monoclonal antibody
6H4, polyclonal anti-p30 antiserum, or mouse preimmune serum. Data represent results from one of two experiments with similar results.
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ters was assessed. To this end, individual preimmune sera and
pools of preimmune sera derived from Prnp/ and Prnpo/o
mice were assayed for binding to tg33 cells in the tg33-based
FACS assay. In no case was significant PrP binding of pre-
immune serum observed (Fig. 6C, right panel, and data not
shown). Furthermore, the very narrow scattering of the blots of
stainings with individual preimmune sera demonstrated the
reliability and reproducibility of the FACS method used (Fig.
6C, bottom right panel). Third, for further verification of the
PrP specificity of serum binding, we included Prnpo/o-derived T
cells in the FACS analysis as negative controls. Even when
strong binding of tg33-derived T cells was observed, no IgG
binding of Prnpo/o-derived T cells was detected, with sera from
either Prnpo/o or Prnp/ mice (Fig. 6C, left panels). Finally,
sera from Prnpo/o and Prnp/ mice immunized with bacteri-
ally produced PrPREC were analyzed by the tg33-based FACS
assay (9, 22). In contrast to the sera obtained from immuniza-
tions with PrPD111 retroparticles, we could not detect any an-
FIG. 4. Immunoelectron microscopic analysis of the particles. Sections through HEK-293FT producer cells transfected with pHIT60/pD-
PrP111 (a) and PrPD111 retroparticles harvested from the cell culture supernatant and concentrated by low-speed centrifugation (b and c) were
stained with the PrP-specific 6H4 antibody and a 10-nm-diameter gold particle-labeled anti-mouse IgG. EGF retroparticles (d and e) were
harvested from pHIT60/pD-EGF-transfected 293FT cells and stained with the anti-EGF (d) or the 6H4 (e) antibody. Bars, 250 nm. Arrowheads
indicate particles with the typical morphology of C-type retroviruses, and arrows indicate pleomorphic vesicles.
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tibodies in Prnp/ mice recognizing the native cell surface-
exposed PrP (Fig. 6D). This failure of PrPREC to circumvent
tolerance in wild-type animals is in line with recently published
data (22). In conclusion, PrPD111 retroparticles are good B-cell
antigens as indicated by strong antibody responses induced in
Prnpo/o mice. Furthermore, PrPD111 retroparticles can induce
low but significant levels of native PrPC-specific IgG antibodies
in mice carrying one or two Prnp wild-type alleles, thus being
superior to recombinant, bacterially expressed PrP.
Immunization of wild-type mice with PrPD111 retroparticles
and different adjuvants. Next we assessed whether even higher
antibody titers against native PrPC could be induced if mice
were immunized with retroparticles emulsified in various
different adjuvants. To this end, mice were injected s.c. with
PrPD111 retroparticles emulsified in CFA and boosted with
antigen in IFA 2 weeks later. Seven days after primary immu-
nization, wild-type (Prnp/) mice showed PrPC-specific IgM
titers that generally were lower than those of i.v. immunized
mice (Fig. 7). However, in single individuals this vaccination
regimen resulted in increased native PrPC-specific IgM titers
(Fig. 7A, days 7 and 14) that switched to the IgG serotype upon
boosting (Fig. 7A, days 28, 63, and 144). Furthermore, PrPD111
retroparticles emulsified in TiterMax, aluminum hydroxide
(alum), or CpG1668 were also tested. Upon s.c. immunization
of mice with PrPD111 retroparticles emulsified in TiterMax or
alum, only low PrPC-specific IgM titers were detectable at day
7, and they rapidly declined at later time points (data not
shown). Under similar experimental conditions, CpG1668 did
not show major adjuvant effects (data not shown). In summary,
PrPD111 retroparticles are effective antigens, irrespective of
whether they are emulsified in adjuvant or not. Notably, the
coexistence of PrPC-specific antibodies and of endogenous
PrPC in PrPD111 retroparticle-immunized mice did not result in
obvious signs of autoimmune side effects.
DISCUSSION
Here we show that retroviral PrP-expressing particles rep-
resent a highly immunogenic PrP vaccine, which, for the first
time, is capable of inducing anti-native PrPC antibody titers in
wild-type mice. Retroviral particles were selected as display
vehicles based on their known ability to accommodate foreign
transmembrane proteins in their envelope membrane. An im-
portant prerequisite for incorporation is efficient cell surface
expression, thus increasing the likelihood of foreign transmem-
brane proteins being present at sites of viral budding. We used
a previously successfully utilized system consisting of a signal
peptide derived from the  light chain and the PDGFR-de-
rived transmembrane domain (4, 6). This approach resulted in
efficient cell surface expression of the EGF molecule as well as
of the C-terminal PrP domains (PrP111 and PrP142) and con-
sequently in highly efficient particle incorporation. However, in
this setting the complete PrP molecule (PrP209) showed
strongly impaired cell surface transport and drastically reduced
efficiency of incorporation into the particles. Besides the fact
that the rather flexible disordered N-terminal domain of PrP
may impede proper folding of the D-PrP209 molecule, while
the globularly structured PrP111 and EGF molecules are well
suited for expression in the retroviral membrane (24), reduced
internalization rates and increased half-lives of PrP truncation
mutants might facilitate the incorporation into VLPs (19).
A hallmark of propagation of the infectious agent of trans-
missible spongiform encephalopathies is the conversion of the
cellular form of PrP into the pathogenic form PrPSc. PrPSc is
thought to contain an increased amount of -structure result-
ing from refolding of -helices in PrPC. Since a truncated PrP
consisting of amino acids 90 to 231 seems to be sufficient to
support prion propagation and thus to induce conversion of
PrPC to PrPSc, the D-PrP142 particle might be amenable to
conversion into PrPSc (8). This possibility will be the subject of
further studies to eventually develop PrPSc-displaying retro-
particles.
Here we used the PrP retroparticles to evoke an immune
response against PrPC upon injection into Prnpo/o and wild-
type mice. The use of virus-like particles is a well-established
approach to generate subunit vaccines (18). Different types of
viruses have been used, including hepatitis B virus and human
FIG. 5. Sera of mice immunized with PrP retroparticles specifically
bind recombinant PrP in ELISA analysis. PrPD111 retroparticles devoid
of adjuvant were injected i.v. into three individual mice of the Prnpo/o
(A), Prnp/o (B), or Prnp/ (C) genotype (open symbols). Seven days
after immunization, serum samples were taken and tested in log2 serial
dilutions (20-fold predilution) for the presence of PrP-specific total
Ig reactive against bacterially expressed PrPREC121-231. As controls, the
anti-PrP monoclonal antibody 6H4, preimmune serum, or sera from
mice injected with EGFD retroparticles were used. Results from one of
two similar experiments are shown.
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papillomavirus. Retrovirus-like particles have been derived
from HIV to develop novel candidate vaccines against AIDS
(34). In that case the extracellular domain of the HIV Env
protein gp120 was linked to the Epstein-Barr virus gp220/350
transmembrane domain to be incorporated into HIV-derived
virus-like particles (5). Although the principle of this approach
is similar to ours, we report here for the first time that retro-
virus-like particles can be used to display antigens of cellular
origin and to induce autoreactive antibody responses.
We assessed the antibody response in mice immunized with
the PrP retroparticles by ELISA with bacterially expressed
PrPREC121-231 applied to plastic and by FACS analysis with T
cells overexpressing PrP on the cell surface. A single i.v. im-
munization with PrP retroparticles was sufficient to induce
FIG. 6. Sera of mice immunized with PrP retroparticles specifically bind the native form of PrP as expressed on the cell surface of tg33-derived
T cells. (A and B) Serum samples were taken 7 (A) or 14 (B) days after i.v. injection of PrPD111 retroparticles into Prnpo/o, Prnp/o, or wild-type
(Prnp/) mice and analyzed for their reactivity against PrP as expressed on T cells derived from PrP-overexpressing tg33 transgenic mice. Five
individuals per group were analyzed (gray lines). IgM (left panels) and IgG (right panels) subtypes were determined. Cells incubated with
preimmune serum (green) or 6H4 (red) were used as controls. (C) Sera from immunized Prnpo/o or wild-type (Prnp/) mice were tested for the
reactivity of IgG subtypes with T cells from Prnpo/o mice (left panels, gray lines) or with T cells from tg33 mice (right panels, gray lines). Preimmune
sera are shown in green in the left panels. Preimmune sera from five individual Prnp/ mice (lower right panel, colored lines) or pooled
preimmune sera from seven Prnpo/o mice (upper right panel, green line) were tested for IgG reactivity against PrP as expressed on tg33 T cells.
(D) Prnpo/o mice immunized with PrPREC in CFA and IFA mounted significant levels of anti-PrP antibodies, whereas Prnp/ mice were
unresponsive to immunizations. Bacterially expressed PrPREC emulsified in CFA and IFA was injected into mice of the Prnpo/o and Prnp/
genotypes (22). At 28 days after immunization, serum samples were analyzed for their IgG reactivity against PrP as expressed on tg33-derived T
cells. Three individuals were analyzed per group (gray lines). Cells incubated with preimmune serum (green) or 6H4 (red) were used as controls.
Histograms in all panels show PrP-specific binding gated on CD3-positive T cells.
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native PrPC binding serum IgM and IgG antibodies in Prnpo/o
mice, the latter of which showed at least as strong binding as
the monoclonal anti-PrP IgG antibody 6H4. The induction of
native PrPC-specific IgM and IgG upon i.v. immunization with
PrP retroparticles of wild-type mice is remarkable and has not
been accomplished in a number of previous, rather disappoint-
ing, immunization studies (2, 9, 11, 12, 16, 25, 27, 28, 30). In a
recent study, immunization with bacterially expressed recom-
binant full-length PrP emulsified in CFA resulted in the induc-
tion of antibodies directed against native PrPC only if mice
aberrantly expressing transgenic PrP under the control of an
oligodendrocyte- and Schwann cell-specific promoter were used,
whereas wild-type controls and all other PrP transgenic mice
tested showed at best serum binding to recombinant PrP ap-
plied to plastic (22).
The magnitude of PrP-specific IgM responses upon i.v. PrP
retroparticle immunization was inversely correlated with the
number of Prnp alleles expressed; i.e., the highest level of
PrP-specific IgM was induced in Prnpo/o mice, whereas inter-
mediate and lower levels were detected in Prnpo/ and Prnp/
mice, respectively. Nevertheless, it is remarkable that overall
similar IgM levels were induced in mice of all three genotypes,
especially at early time points. Obviously, immunologic host
tolerance seems to be predominantly manifested on the T-cell
level, so that in our experimental setting the magnitude of
PrPC-specific IgM responses is only gradually influenced by the
expression level of the PrP self-determinant (1, 13, 31). Ac-
cordingly, the switch from the IgM to the IgG isotype of PrPC-
specific antibodies is less pronounced in wild-type animals than
in Prnpo/o mice. Probably T-helper determinants accounting
for the IgG switch in wild-type animals are provided by MLV-
related antigens. In conclusion, it is remarkable that host tol-
erance left enough room for the induction of potentially auto-
reactive PrP-specific antibodies. This finding is in line with
previous observations that PrP-specific B cells can develop in
the presence of endogenously expressed PrP in 6H4 trans-
genic mice (14). Further studies will reveal whether the induced
antibody levels suffice to prevent prion disease and whether
PrP retroparticles will hold promise as an antiprion vaccine.
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